Skip to content

13F-HR filed by Versant Venture Management, LLC

Versant Venture Management, LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-13 21:56:03 UTC, with 8 holding rows worth $109,097,271.

Accession
0001193125-26-460919
Filed
2026-11-13
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 8 entries on the cover page, a total value of $109,097,271 stated on the cover page (in dollars after the unit check, H1), rows summing to $109,097,271 with VALUE read as dollars as filed, 13F file number 028-16849. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
MONTE ROSA THERAPEUTICS INC61225M102COM3,180,780$37,946,705dollars as filed
CENTURY THERAPEUTICS INC15673T100COM12,166,109$20,804,046dollars as filed
CONTINEUM THERAPEUTICS INC CL A21217B100Stock1,292,628$17,347,068dollars as filed
JADE BIOSCIENCES INC008064206COM NEW991,783$13,934,551dollars as filed
LENZ THERAPEUTICS INC52635N103COM2,656,888$10,202,450dollars as filed
CRISPR THERAPEUTICS AG NAMEN AKTH17182108Stock148,831$8,233,331dollars as filed
SKYE BIOSCIENCE INC COM83086J309Stock250,962$404,049dollars as filed
Tempest Therapeutics, Inc.87978U108Common Stock269,772$225,071dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001193125-26-460919this filing2026-11-13